Omikon BA.4/5 will become a global leading strain, which is more likely to break through sex infection

The European Centers for Disease Control and Prevention said on the 13th that the two new sub -variants BA.4/5 of the new crown virus mutant strain Omikon is more than other strains in Europe and will become the dominant strain in Europe. This trend has also been confirmed in other countries.

The latest series of scientific research shows that the reason why Omikon BA.4/5 is more and more likely to become a new global leading strain in the future -because it has stronger communication and re -infection ability again Essence As they become major popular plants, the number of global residents and deaths may increase.

Standing in Europe and the United States

The European Centers for Disease Control and Prevention warned in a latest notice on the 13th that although most European countries BA.4/5 currently account for a lower proportion compared to BA.2, this situation has reversed in some countries reversed in some countries. ——In Portugal, as of June 9, the country's BA.4/5 cases have accounted for 87%of new cases, of which BA.5 is higher, and the overall number of cases has increased.

It is worth noting that in the epidemic caused by the previous wave of BA.2, Portugal has not surged.

European illness and control said that the growth advantage of BA.4/5 shows that they will occupy the leading position throughout Europe in the next few weeks, which may lead to an increase in new crown cases in the next few weeks.

According to data from the National Bureau of Statistics (ONS), due to BA.4/5, England and Northern Ireland have recently appeared "rising slightly". The number of British hospitalizations also increased by 10%per week.

The statistics of the American Centers for Disease Control and Prevention (CDC) on the other side of the ocean show that the current BA.4/5 cases in the United States have accounted for 21%of the total, and its growth rate is higher than the currently dominated BA.2.12. 1. It is expected that BA.4/5 is likely to become the main strain in the United States in the near future.

BA.4/5 was first detected in South Africa in January and February this year, respectively. They became the country's main strain in May and brought a new wave of epidemic.

Subsequently, the WHO added BA.4/5 to the monitoring list in March this year. In May, the European CDC upgraded it to the highest -level alert.

BA.4/5 is the two Asian scores of Omikon's entry branch. They share the same mutations of the previous subtypes of Omikon and have different new mutations at the same time. Compared with the currently dominant strain BA.2, new key mutations in the spiny protein of BA.4/5 include L452R and F486V. The main changes brought by these mutations are that BA.4/5 is increasingly able to escape the existing immune system of the human body, causing people who have vaccinated or have infected with the new crown virus infection again.

However, there are no signs that BA.4/5 will lead to severe diseases or deaths compared with the previous Omircor's mutant strains. As of June 1, although the severity indicators of Portugal's disease (hospitalization, ICU, and death) were lower than the level at the peak of the last Omikon, the weekly increase was increased.

Immune escape stronger

The latest series of research on the new characteristics of BA.4/BA.5 will help countries around the world to revise epidemic prevention and vaccination strategies in the world and respond to a new wave of epidemic that may come to this summer.

On June 8th, the international authoritative academic journal "Cell" published the research of a group of scientists at Oxford University on BA.4/5 serum science characteristics. The core results of this study show The serum of the vaccinator does have a significant escape. 2) The two new mutations of L452R and F486V are the main reasons for BA.4/5 to have a significant immune escape than BA.2.

Researchers use a series of vaccines and natural immunocal serums and panels of monoclonal antibodies to study the neutralization of BA.4/5. Compared with BA.1 and BA.2, the BA.4/5 shows a decreased serum neutral rate for three -dose vaccination from Astraon or Pfizer. In addition, the serum of the breakthrough infected from the use of the BA.1 vaccine has also decreased significantly on the neutralization of BA.4/5, which shows that the possibility of repeatedly infected with the infected infection.

One of the researchers, Ren Jingshan, a researcher at Oxford University in the United Kingdom, told Peng Mei News (www.thepaper.cn): "We found that Omikon BA.4/5 did have more stabbing protein mutations than other strains. It may be caused by the immunization escape after vaccination or infection. "

Researchers concluded: "Although it is impossible to say what the next evolution of the new coronal virus (SARS-COV-2) will be, it is certain that the virus will continue to escape from its immune escape and may continue to branch in the Omiko branch branch. In the middle evolution, it may also be seen in a brand new branch, such as the previous from Delta to Omikon. SARS-COV-2 still has a lot of space and reorganization capabilities, which may produce more radical changes. Sentences, the ability to escape the immunization system will become stronger. "

Almost at the same time, a pre -print book of a study of Columbia University scholars in the United States also concluded that the main mutant sites of BA.4/5 not only make the strain more likely to escape from immunization, but also respond to mutation by replying to mutations. (Editor's Note: After the second mutant and fully or partially restored to the original genotypes and expression after the second mutation), the strain restored the adaptability, which is easier to escape and neutralizes, and it is more likely to produce breakthrough infections. Essence Regarding these two studies, Wang Linfa, a professor at the National University of Singapore and Coronatte Virus expert, told Peng Mei News that BA.4/5 is even stronger than BA.1/2 in terms of escaping neutralization of antibody media. "From the perspective of cross-neutralization, I think BA.4/5 represents different serum types different from the original version of SARS-COV-2."

In addition to immune escape, people also care about the pathogenicity of BA.4/BA.5? A study conducted by the University of Tokyo's Kei Sato team evaluated BA.4 and BA.5's virinology characteristics in vitro and in vivo. It shows that the replication efficiency of BA.4/BA.5 in human lung cells (breathing epithelial cells) is higher than BA.2. In addition, infection experiments using hamsters show that BA.4/5 is more pathogenic than BA.2.

"In animal models (infected hamsters), BA.4/5 is indeed more lung damage than BA.2." Japanese researchers warned that "a simple assumption that has no conclusive evidence is that SARS-COV -2 will evolve in a manner weakened. Our research refutes this view. Our observation strongly shows that SARS-COV-2 may not be evolved in a manner that weakens its pathogenicity. "Researchers pointed out.

However, a number of scholars pointed out to Peng Mei News that the conclusions of the above -mentioned body and animal experiments are not enough to come to the conclusion of BA.4/5 more pathogenic on the human body.

Analysis of research scholar and doctor of immunology at the National Institute of Health and PhD in immunology believes that comprehensive research shows that it can be determined at present, the adaptability of BA.4/5 to the human body is more adaptable, so that it is replacing other strains to become the main poisonous poison Plant; BA.4/5 has a significant escape from the serum of the vaccinator, and it is more prone to breakthrough infection, which will bring new challenges to the future epidemic prevention.

Several scientists have pointed out that the emergence of a mutant strain that can more effectively escape immune protection may greatly deteriorate the new crown epidemic, so it is worth paying attention to. This summer, the world may have to continue to live under the shadow of Ormico.

Source: Surging News

- END -